Moreover, the silencing of BMAL1 has been found to inhibit glycolysis, thereby promoting M1 polarization via the LDHA/lactate axis, further inhibiting M2 polarization and angiogenesis in GBM cells, and to sensitize GBM cells to bevacizumab [112]. This evidence concerns the gene LDHA and glioblastoma.